Dienogest mediates midkine suppression in endometriosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
STUDY QUESTION: What are the effects of dienogest (DNG) on midkine (MK) production in women with endometriosis? SUMMARY ANSWER: DNG-mediated down-regulation of MK in vivo and in vitro. WHAT IS KNOWN ALREADY: DNG is an oral progestin that alleviates painful symptoms of women with endometriosis with a favourable tolerability and safety profile. Its effects on MK, a growth factor that plays an important role in endometriosis, have not yet been investigated. STUDY DESIGN, SIZE, DURATION: Prospective in vivo study on 283 patients subjected to laparoscopy for benign pathologies in a University hospital and in vitro cultures of primary endometrial stromal cells (ESC) from 6 of these women with histologically confirmed endometriosis. PARTICIPANTS/MATERIALS, SETTING, METHODS: MK concentrations in the peritoneal fluid (PF) of women were measured by ELISA and compared based on endometriosis status and the use of DNG. A subsequent in vitro analysis with ESC was used to confirm the direct influence of DNG and other progestins including, norethisterone acetate (NETA) and medroxyprogesterone acetate (MPA) on MK mRNA production. MAIN RESULTS AND THE ROLE OF CHANCE: The final study population consisted of 253 women. Of these, 165 suffered from endometriosis, with 62 of them taking DNG (DNG group) and 103 taking no hormone treatment (non-DNG group) during at least 3 months before surgery. Another 88 women were endometriosis free (non-endometriosis group). The concentration of MK was highest in the PF of women in the non-DNG group (median 5.26 ng/ml, IQR 2.74-8.46). Significantly lower concentrations were found in the non-endometriosis group (median 3.51 ng/ml, IQR: 1.90-7.53, P = 0.028). The lowest concentrations were found in the DNG group (median 2.44 ng/ml, IQR: 1.12-4.70, P < 0.0001 versus non-DNG group, P = 0.048 versus non-endometriosis group). The treatment of primary cultured ESC with DNG (10(-5) M) suppressed MK mRNA production (P = 0.016), whereas MPA (P = 0.109) and NETA (P = 0.422) at same concentrations did not show a similar effect. LIMITATIONS, REASONS FOR CAUTION: The non-randomized design of the study. WIDER IMPLICATIONS OF THE FINDINGS: These findings could indicate a direct effect of DNG on endometriotic cells that could contribute to its effectiveness in the treatment of this disease. STUDY FUNDING/COMPETING INTERESTS: Funding was received from Swiss National Science Foundation (Grant No. 320030_140774). M.D.M. has received fees for speaking at scientific meetings from Bayer. The other authors have no conflicts of interest to declare.The authors state that the manufacturer of dienogest has in no way influenced the performance or outcomes of this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211
Eskenazi, B., & Warner, M. L. (1997) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70302-8 · Cited by 1,617
Cosson, M., Querleu, D., Donnez, J., Madelenat, P., Konincks, P., Audebert, A., & Manhes, H. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)03270-8 · Cited by 153
Horie, S., Harada, T., Mitsunari, M., Taniguchi, F., Iwabe, T., & Terakawa, N. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.042 · Cited by 146
Okada, H. (2001) · Molecular Human Reproduction · doi:10.1093/molehr/7.4.341 · Cited by 104 · cited 1×
“Previous evidence supports a similar progesterone receptor (PR)-mediated activity of DNG and other progestins on protein production and secretion in ESC from women with endometriosis (Okada et al., 2001; Horie et al., 2005; McCormack, 2010; Grandi et al., 2016).”
BackgroundNatural killer T cell subsets in eutopic and ectopic endometrium: a fresh look to a busy corner
Laganà, A. S., Triolo, O., Salmeri, F. M., Granese, R., Palmara, V. I., Ban Frangež, H., Vrtčnik Bokal, E., & Sofo, V. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-4004-7 · Cited by 67
On-label and off-label drug use in the treatment of endometriosis
Quaas, A. M., Weedin, E. A., & Hansen, K. R. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.01.006 · Cited by 45 · cited 7×
“The treatment of primary cultured ESC with DNG (1025 M) suppressed MK mRNA production (P ¼ 0.016), whereas MPA (P ¼ 0.109) and NETA (P ¼ 0.422) at same concentrations did not show a similar effect. limitations, reasons for caution: The non-randomized design of the study. wider implications of the findings: These findi…”
BackgroundInfluential
Cited by
Reis, F. M., Coutinho, L. M., Vannuccini, S., Batteux, F., Chapron, C., & Petraglia, F. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa009 · Cited by 166
Römer, T. (2018) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-4864-8 · Cited by 82
Endometriosis, especially mild disease: a risk factor for miscarriages
Kohl Schwartz, A. S., Wölfler, M. M., Mitter, V., Rauchfuss, M., Haeberlin, F., Eberhard, M., von Orelli, S., Imthurn, B., Imesch, P., Fink, D., et al. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.08.025 · Cited by 63
Dienogest for Treatment of Endometriosis in Women: A 28-Week, Open-Label, Extension Study
Yu, Q., Zhang, S., Li, H., Wang, P., Zvolanek, M., Ren, X., Dong, L., & Lang, J. (2019) · Journal of Women's Health · doi:10.1089/jwh.2018.7084 · Cited by 34
Metadata
- Authors
- Nirgianakis, K., Grandi, G., McKinnon, B., Bersinger, N., Cagnacci, A., & Mueller, M.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-07-13
- Volume
- 31
- Issue
- 9
- Pages
- 1981-1986
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2474395965
- Cited by
- 31
- References
- 7
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.